California Kids Cancer Comparison leader David Haussler said the project's workflow was able to match 100 percent of tumor samples it tested to possible treatments.
A proportion of pediatric ALL patients appear to have germline TP53 mutations associated with later diagnoses, poorer outcomes, and increased secondary cancer risk.
New studies suggest low-, intermediate-, and high-methylation subgroups exist in juvenile myelomonocytic leukemia, potentially offering insights into patient outcomes.
A new consensus report suggests RB1 testing and genetic counseling to stratify risk and guide ophthalmic screening in kids with affected family members.
Genome and transcriptome sequences from hundreds of pediatric cancer cases led to somatic mutations and fusions suspected of producing potentially targetable antigens.
When investigators retraced recurrent mutations, expression changes, and methylation shifts in hundreds of Wilms tumor case, they identified two main pathways.
Hospital will partner with several other institutions in this effort to support data-driven research into pediatric cancers and structural birth defects.
The study is the pediatric counterpart to an ongoing precision medicine study in cancer patients 18 years and older.
With mutation, expression, and epigenetic features from hundreds of medulloblastoma tumors, researchers characterized key features of brain tumor subtypes.
Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.